- Home
- MNMD
as 11-15-2024 4:00pm EST
Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 485.5M | IPO Year: | N/A |
| Target Price: | $28.75 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.44 - $12.22 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Mind Medicine (MindMed) Inc. (MNMD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sullivan Mark | MNMD | Chief Legal Officer | Sep 25 '24 | Sell | $5.98 | 4,430 | $26,491.40 | 177,716 | |
| Barrow Robert | MNMD | Chief Executive Officer | Sep 25 '24 | Sell | $5.98 | 19,771 | $118,230.58 | 545,772 | |
| Karlin Dan | MNMD | Chief Medical Officer | Sep 25 '24 | Sell | $5.98 | 6,871 | $41,088.58 | 344,656 | |
| Liao Carrie | MNMD | Chief Accounting Officer | Sep 25 '24 | Sell | $5.98 | 2,352 | $14,064.96 | 99,543 | |
| GRYSKA DAVID W | MNMD | Director | Aug 23 '24 | Buy | $5.98 | 3,500 | $20,930.00 | 17,351 | |
| Barrow Robert | MNMD | Chief Executive Officer | Aug 19 '24 | Buy | $6.22 | 1,000 | $6,215.00 | 565,543 |
Latest Mind Medicine (MindMed) Inc. News
MNMD Breaking Stock News: Dive into MNMD Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) market cap touched US$601m last week, benefiting both retail investors who own 41% as well as institutions
Business Wire
4 days ago
MindMed to Participate in Upcoming Investor Conferences
Business Wire
10 days ago
MindMed Reports Third Quarter 2024 Financial Results and Business Updates
Business Wire
24 days ago
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update
TipRanks
a month ago
Mind Medicine assumed with an Outperform at Leerink
Business Wire
2 months ago
MindMed Announces New Employee Inducement Grants
Business Wire
2 months ago
MindMed to Participate in September Investor Conferences
Business Wire
3 months ago
MindMed Reports Second Quarter 2024 Financial Results and Business Updates
Compare MNMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MNMD Mind Medicine (MindMed) Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.